Premium
Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition
Author(s) -
Sen Abhijit,
Papadimitriou Nikos,
Lagiou Pagona,
PerezCornago Aurora,
Travis Ruth C.,
Key Timothy J.,
Murphy Neil,
Gunter Marc,
Freisling Heinz,
Tzoulaki Ioanna,
Muller David C.,
Cross Amanda J.,
Lopez David S.,
Bergmann Manuela,
Boeing Heiner,
Bamia Christina,
Kotanidou Anastasia,
Karakatsani Anna,
Tjønneland Anne,
Kyrø Cecilie,
Outzen Malene,
Redondo MaríaLuisa,
Cayssials Valerie,
Chirlaque MariaDolores,
Barricarte Aurelio,
Sánchez MariaJose,
Larrañaga Nerea,
Tumino Rosario,
Grioni Sara,
Palli Domenico,
Caini Saverio,
Sacerdote Carlotta,
BuenodeMesquita Bas,
Kühn Tilman,
Kaaks Rudolf,
Nilsson Lena Maria,
Landberg Rikard,
Wallström Peter,
Drake Isabel,
Bech Bodil Hammer,
Overvad Kim,
Aune Dagfinn,
Khaw KayTee,
Riboli Elio,
Trichopoulos Dimitrios,
Trichopoulou Antonia,
Tsilidis Konstantinos K.
Publication year - 2018
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.31634
Subject(s) - medicine , prostate cancer , prospective cohort study , hazard ratio , cancer , proportional hazards model , confidence interval , epidemiology , cohort , cohort study , lower risk , breast cancer
The epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow‐up. Data on coffee and tea consumption were collected through validated country‐specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 vs . 12 mL/day) the HRs were 1.02 (95% CI, 0.94–1.09) and 0.98 (95% CI, 0.90–1.07) for risk of total prostate cancer and 0.97 (95% CI, 0.79–1.21) and 0.89 (95% CI, 0.70–1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.